

Archer CEO to Present at Upcoming Investor and Semiconductor Conferences

Highlights

- Archer Materials Limited Chief Executive Officer Dr Simon Ruffell will present at the 15th Annual Australian Microcap Investment Conference in Melbourne on Tuesday, 20 October 2026.
- Dr Ruffell will also present at Semiconductor Australia 2026 in Sydney on Thursday, 22 October 2026.

Archer Materials Limited (**ASX: AXE**) advises that Chief Executive Officer Dr Simon Ruffell will present at the following upcoming conferences:

15th Annual Australian Microcap Investment Conference

- **Date:** Tuesday, 20 October 2026
- **Time:** 12:15pm (AEDT)
- **Location:** Melbourne, Australia
- **Conference information:** <https://www.microcapconferences.com/event/15AMIC/summary>

Semiconductor Australia 2026

- **Date:** Thursday, 22 October 2026
- **Time:** 11:00am (AEDT)
- **Location:** ILUMINA, Sydney
- **Conference information:** <https://www.semiconductoraustralia.com/info>

The Company's updated Investor Presentation is enclosed with this announcement.

The Board of Archer authorised this announcement to be given to ASX.

Investor enquiries

investors@archermaterials.com

Media enquiries

Stef Winwood
stef@ruthlessventures.com
+61 433 307 853

About Archer

Archer is a quantum technology company that operates within the semiconductor industry. The Company is developing advanced semiconductor devices, including chips relevant to quantum computing, sensing, and medical diagnostics. Archer utilises its global partnerships to develop these technologies for potential deployment and use across multiple industries. www.archerx.com.au



Archer Materials Limited

ASX: AXE

Simon Ruffell
Chief Executive Officer

Australian Microcap Investment Conference

October 2026

Australia's only listed pure-play quantum company



Strategic partnership with IonQ

Bringing the world's leading compute power, IonQ Forte computing to Australia



Deep technical expertise

In-house quantum hardware, software and applications team.



Quantum Software

Quantum machine learning & applications IP



Strategic IP

40+ patents filed globally across quantum and sensing, plus a growing quantum-algorithm IP base.



Quantum Hardware

Carbon-based qubit & sensing technology




Australian operating base

ASX-listed (ASX: AXE), Australian-incorporated; operations in Sydney and Adelaide (Lot Fourteen).

Our portfolio

Complementary technologies built on a common materials foundation to solve complex quantum problems



IonQ Quantum Compute Power

1

Near-term revenue. World-class capability.

- Strategic partnership with global leader IonQ.
- Provides direct access to IonQ Forte Enterprise, the most powerful commercially available quantum compute power.
- Quantum Commercial Pilot to convert access into commercial pipeline development.



Quantum Software & Hardware

2

Quantum Software & PQC Readiness

- Archer–CSIRO QML program for financial services
- Moving from simulation to IonQ hardware
- Quantum-advantage benchmarks vs classical methods

Graphene Based Quantum Hardware

- Developing graphene qubit chips for next-gen ruggedised and manufacturable quantum devices




Biochip Platform

3

Medical diagnostics platform for global markets.

- Miniaturised chip-based biosensor bringing clinical-grade diagnostics to the point of care.
- Developed with IMEC, the biochip enables fast, accurate, and low-cost digital testing.
- Opens new applications in medical health.
- A standalone commercial asset with near-term clinical trials and licensing potential.

Quantum is moving from research to a multi-billion-dollar market



~\$129B

in annual revenue for quantum technology providers at maturity (2040)

Total market grows from ~\$2B today to \$27B by 2030 and \$129B by 2040, led by quantum computing.

Source: BCG analysis (total quantum technology market by segment, US\$B). Quantum computing assumes 20% technology-provider share of value created.

IonQ Strategic Partnership

World leading compute
power

ARCHER

Partnering with the world's leading quantum platform company



~US\$21B

Market cap (NYSE: IONQ)

US\$3.3B

Cash & investments

US\$130M

FY25 revenue (+202%)

US\$260–270M

FY26 revenue guidance

1,300+

Staff across 30+ countries

99.99%

Two-qubit gate fidelity (record)

- ✓ Full-stack quantum platform: computing, networking, sensing & security
- ✓ Trapped-ion architecture; datacentre-ready Forte and next-gen Tempo systems
- ✓ Technology roadmap toward 2 million qubits by 2030
- ✓ Customers and partners include AWS, AstraZeneca and NVIDIA
- ✓ Selected for the US DARPA HARQ program in modular quantum computing

Sources: IonQ SEC filings and company announcements (FY2025 results, Q1 2026); figures as reported. Market capitalisation as at June 2026.

Bringing commercial quantum utility to Australia

Phase 1: Build quantum use cases and develop customer pipeline

1



Bring cloud Quantum Computing to Australia

Provide access to IonQ Forte- and Tempo-class systems alongside Archer know-how to Australian customers across various industries.

2



Build proprietary products & IP

Develop quantum algorithms and applications for customers. Archer owns its inputs and results, creating defensible intellectual property.

Phase 2: Strategic Objectives

3



Onshore Quantum Computing capability

Use Archer's quantum R&D, software and partnerships to build a strong position to establish local systems.


4



Build customers, applications & subscriptions

Implement commercial scale applications with customers. Build revenue pipeline as well provide sovereign capability to sectors like defence. Grow the computing ecosystem.

1–2 are enabled and underway under the signed agreement. 3–4 are strategic objectives — not yet contracted — that the partnership is designed to position Archer to pursue.



Owned Quantum Software & Hardware

Quantum machine learning and
applications IP

Quantum machine learning, built for real-world value

- ✓ Partnered with CSIRO to develop quantum machine learning (QML) models for fraud detection
- ✓ Initial outputs: prototype QML models and performance benchmarks on simulated financial datasets
- ✓ The QML framework applies to healthcare, defence & aerospace, cybersecurity
- ✓ Builds defensible IP and the first steps of a customer application pipeline feeding the IonQ partnership



How graphene qubits solve multiple barriers to quantum hardware

Quantum computers process information and solve problems that are prohibitive for classical computers— but face significant scale-up and manufacturing barriers. Archer is developing ruggedised next-generation graphene-based hardware designed to operate in real-world environments.



Ruggedised operation for real-world environs

Graphene based quantum hardware will reduce the engineering challenges and overheads required for utility scale, real-world operation




Superior coherence times and stability

Graphene qubits offer extreme stability and control for reliable operation and future fault tolerance quantum hardware



Designed for future scalable manufacturing

Manufacturing and scalability being designed from the development phase to integrate with today's semiconductor fabrication techniques



The background image is a blurred photograph of a laboratory setting. A person wearing a white lab coat and blue nitrile gloves is using a pipette to transfer a liquid from a small vial into a multi-well plate. The scene is dimly lit, with a blueish tint. A red horizontal bar is visible in the lower foreground, partially obscuring the bottom of the image.

Biochip Platform

Point-of-Care Medical Diagnostics
platform for global markets

One sensing chip, a platform across markets



Core sensing platform — chip-based ion detection, microfluidics & functionalization chemistry



Lithium — Blood Diagnostics (IVD)

Bipolar disorder therapeutic drug monitoring — lead clinical application


IN DEVELOPMENT



Potassium — Blood Diagnostics (IVD)

Chronic kidney disease & heart failure monitoring — next clinical application

NEXT APPLICATION



Calcium — Industrial Process Monitoring

Real-time sensing for dairy processing — a large adjacent market under investigation

EXPLORATORY



Multi-Analyte Panels

Same chip architecture, multiple ion-selective chemistries in parallel — panels tailored to each market's workflow


PLATFORM MECHANISM

Beyond potassium and lithium blood diagnostics, Archer is investigating other medical & industrial applications — and building toward multi-analyte panels on the same core architecture.

One sensing architecture — chip-based ion detection + microfluidics + readout electronics. Only the surface chemistry changes to unlock a new ion, a new market, or a new panel.

The IP is in the chip and its chemistry – not the box around it

CORE IP — PATENT-PROTECTED



- **Sensing chip**
Proprietary silicon ion-sensing architecture and design
- **Functionalization layers**
Proprietary surface chemistry and processing enabling accurate and rapid sensing
- **Manufacturing process steps**
Proprietary fabrication & functionalization methods that make the chip reproducible at volume

This is where Archer's patents and know-how sit — and why no prior point-of-care attempt has matched this accuracy and reliability.

LEVERAGING PROVEN COMPONENTS



Reader



Cartridge & fluidics

- Disposable microfluidic cartridges — mature, low-cost consumable manufacturing
- Fluidic handling — established microfluidics engineering and design patterns
- Electronic reader / readout hardware — standard embedded electronics and low-cost manufacturing

Archer integrates its proprietary chip and readout techniques into components the diagnostics industry has already optimised for years — lowering cost and de-risking manufacturing.

A global network advancing Archer's technology

EPFL

SWITZERLAND

EPFL

Quantum chip components



BELGIUM

imec

Biosensor manufacturability & integration



UNITED STATES

IonQ

Full stack quantum platform & merchant



UNITED KINGDOM

Paragraf

Potassium sensing accuracy & reliability



CANADA

HyliDx


Biochip cartridge & CKD regulatory pathway



AUSTRALIA

CSIRO

Quantum machine learning



AUSTRALIA

Emergence
Quantum

Quantum sensing integration

Investment summary



Sovereign quantum first-mover

Positioning to deliver Australia's first commercial sovereign quantum computing platform.



Australia's only listed pure-play

The only pure-play quantum exposure on the ASX, with hardware and software platforms.



Tier-one IonQ partnership

A multi-year agreement with the world's leading quantum platform company.



Low-capex, high-margin model

Develops and prototypes in-house, then scales via foundry, partner and reseller models.



Expanding IP portfolio

40+ patents filed globally, plus growing quantum-algorithm and applications IP.



Deep technical leadership

A deep-tech team backed by a global network of scientific advisors and partners.

Board & Management



Greg English
Executive Chair



Bernadette Harkin
Non-Executive Director



Andrew Just
Non-Executive Director



Dr Simon Ruffell
CEO



Dr Andrew Sexton
Head of Engineering



William Wang
Commercial Engagement
Manager



Clarissa Driver
Head of People &
Operations



Thank you

Building Australia's quantum computing capability

Archer Materials Limited

archerx.com.au

Disclaimer

This presentation (**Presentation**), together with any information communicated by Archer Materials Limited (ACN 123 993 233) (the **Company** or **Archer**), in any presentation or discussion relating to this Presentation (collectively, **Information**) is confidential, and has been prepared by the Company on the condition that it is for the exclusive information and use of the recipient. The Information is proprietary to the Company and may not be disclosed to any third party or used for any other purpose without the prior written consent of the Company. Except as otherwise expressly stated in this Presentation, the Company has not authorised any person to give any information or make any representation which is not contained in this Presentation.

Not an Offer

The information contained in the Presentation is for information purposes only. The Presentation does not comprise a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with the Australian Securities and Investments Commission) or any other law. The Presentation also does not constitute or form part of any invitation, offer for sale or subscription or any solicitation for any offer to buy or subscribe for any securities nor shall they or any part of them form the basis of or be relied upon in connection therewith or act as any inducement to enter into any contract or commitment with respect to securities. In particular, this presentation may not be released to US wire services or distributed in the United States. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 or the securities laws of any state or other jurisdiction of the United States and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws. The distribution of this presentation in the United States and elsewhere outside Australia may be restricted by law.

Not Investment Advice

The information contained in the Presentation is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. Please note that, in providing the Presentation, the Company has not considered the objectives, financial position or needs of any particular recipient. The information contained in the Presentation is not a substitute for detailed investigation or analysis of any particular issue and does not purport to be all of the information that a person would need to make an assessment of the Company or its assets. Current and potential investors should seek independent advice before making any investment decisions in regard to the Company or its activities.

Summary Information

The Presentation does not purport to be all inclusive or to contain all information about the Company or any of the assets, current or future, of the Company. The Presentation contains summary information about the Company and its activities which is current as at the date of the Presentation. The information in the Presentation is of a general nature and does not purport to contain all the information which a prospective investor may require in evaluating a possible investment in the Company or that would be required in a prospectus or product disclosure statement or other offering document prepared in accordance with the requirements of Australian law.

Forward looking statements

The Presentation includes “forward looking statements” within the meaning of securities laws of applicable jurisdictions. Forward looking statements can generally be identified by the use of the words “anticipate”, “believe”, “expect”, “project”, “forecast”, “estimate”, “likely”, “intend”, “should”, “could”, “may”, “target”, “plan”, “guidance” and other similar expressions. Indications of, and guidance on, future earnings or dividends and financial position and performance are also forward looking statements. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company and its officers, employees, agents or associates, that may cause actual results to differ materially from those expressed or implied in such statement. Actual results, performance or achievements may vary materially from any projections and forward looking statements and the assumptions on which those statements are based. Given these uncertainties, recipients are cautioned to not place undue reliance on any forward looking statement. Subject to any continuing obligations under applicable law the Company disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in this document to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based.